Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three distinct drugs with different mechanisms of action and clinical applications: - **Terbutaline**: A selective beta-2 adrenergic receptor agonist used to prevent bronchospasm in patients with asthma, bronchitis, emphysema, and other lung diseases. It works by relaxing the muscles in the bronchial tubes, increasing airflow through the lungs. - **Metoprolol**: A beta-1 selective beta-blocker that becomes progressively nonselective at higher doses. It's used to treat heart failure, hypertension, and other cardiovascular conditions. - **Carvedilol**: A non-selective beta-adrenergic antagonist that also has alpha-1 blocking properties. It's used to treat mild to severe chronic heart failure, hypertension, and left ventricular dysfunction following myocardial infarction. This combination is not a standard therapeutic regimen but has been studied in research contexts to understand drug interactions, particularly in patients who might require both bronchodilation and beta-blockade for coexisting conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on terbutaline + metoprolol + carvedilol.